Aura Biosciences 과거 수익 실적

과거 기준 확인 0/6

Aura Biosciences의 수입은 연평균 -24.6%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 증가했습니다(19.1%).

주요 정보

-24.6%

수익 성장률

86.1%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	n/a
자기자본 수익률	-47.6%
순이익	n/a
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

업데이트 없음

Recent updates

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10

수익 및 비용 분석

Aura Biosciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGM:AURA 수익, 비용 및 수입 (USD Millions )
날짜	수익	G+A 비용	R&D 비용
30 Sep 24	-83	22	71
30 Jun 24	-81	21	70
31 Mar 24	-79	20	68
31 Dec 23	-76	20	65
30 Sep 23	-71	20	58
30 Jun 23	-68	19	54
31 Mar 23	-63	19	48
31 Dec 22	-59	18	42
30 Sep 22	-55	17	37
30 Jun 22	-52	15	32
31 Mar 22	-51	13	29
31 Dec 21	-46	10	25
30 Sep 21	-40	8	21
30 Jun 21	-33	6	17
31 Mar 21	-29	5	16
31 Dec 20	-30	4	18

양질의 수익: AURA 은(는) 현재 수익성이 없습니다.

이익 마진 증가: AURA 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: AURA 은(는) 수익성이 없으며 지난 5년 동안 연간 24.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 AURA 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: AURA 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( 16.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: AURA 현재 수익성이 없기 때문에 마이너스 자본 수익률( -47.64% )을 갖습니다.

Aura Biosciences 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Recent updates

Aura Biosciences, Inc. Announces Positive Early Data from an Ongoing Phase 1 Clinical Trial of Bel-sar (AU-011) in Patients with NMIBC

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Aura Biosciences, Inc. Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as A First- Line Treatment for Early-Stage Choroidal Melanoma

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Insider selling

Founder recently sold US$121k worth of stock

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Independent Chairman of the Board recently bought US$1.4m worth of stock

Founder notifies of intention to sell stock

Aura Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $99 million.

Aura Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Founder recently sold US$65k worth of stock

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Independent Chairman of the Board recently bought US$168k worth of stock

Aura Biosciences, Inc. Announces Executive Changes

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting

Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences Inc. to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences Receives Fda Fast Track Designation for Belzupacap Sarotalocan (Au-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 2500 Value Index

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AUu-011) Versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Aura Biosciences Present Updates Belzupacap Sarotalocan (Au-011) Data on Multiple Studies At the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Independent Chairman of the Board recently bought US$716k worth of stock

Aura Biosciences, Inc. Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences, Inc. Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기